Table 2.

Primary efficacy assessment of the change in the Patient’s Assessment of Arthritis Pain scored using a visual analogue scale (VAS) from baseline to week 6 in patients with osteoarthritis of the knee who were treated with either 200 mg celecoxib once daily, 800 mg ibuprofen three times daily or placebo.

	Celecoxib 200 mg once daily	Ibuprofen 800 mg three times daily	Placebo
Change from baseline in Patient’s Assessment of Arthritis Pain (VAS) – PPA Population
Change from baseline
n	122	123	56
Mean (unadjusted)	−34.5	−32.8	−28.4
SE mean	2.23	2.28	3.41
	Ibuprofen–Celecoxib	Ibuprofen–Placebo	Celecoxib–Placebo
Difference in LS means	2.76	−2.50	−5.26
SE	3.12	3.94	3.96
95% CI	−3.38, 8.90	−10.25, 5.25	−13.06, 2.54
Statistical significancea	NS	NS	NS
Change from baseline in Patient’s Assessment of Arthritis Pain (VAS) – MITT Population
Change from baseline
n	151	151	78
Mean (unadjusted)	−31.6	−29.1	−21.3
SE mean	2.06	2.12	3.06
	Ibuprofen–Celecoxib	Ibuprofen–Placebo	Celecoxib–Placebo
Difference in LS means	3.72	−5.69	−9.41
SE	2.90	3.53	3.51
95% CI	−1.98, 9.43	−12.63, 1.24	−16.31, −2.52
Statistical significancea	NS	NS	P = 0.0076

^aAnalysed using a general linear model with treatment and centre as fixed effects and baseline score as a covariate.

PPA, per-protocol analysis; CI, confidence interval; MITT, modified intent-to-treat; LS, least squares; NS, no statistically significant between-group differences (P ≥ 0.05).